Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk?
作者信息
Inciardi Riccardo M, Adamo Marianna, Lupi Laura, Metra Marco
机构信息
Institute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
出版信息
Eur Heart J. 2020 Jul 1;41(32):3094. doi: 10.1093/eurheartj/ehaa576.
Abstract
摘要
相似文献
1
Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk?新冠疫情时代的心房颤动：单纯的旁观者还是风险增加的标志物？
Eur Heart J. 2020 Jul 1;41(32):3094. doi: 10.1093/eurheartj/ehaa576.
2
Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients?心房颤动是否应被视为COVID-19患者预后较差的心血管危险因素？
Eur Heart J. 2020 Jul 1;41(32):3092-3093. doi: 10.1093/eurheartj/ehaa509.
3
New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease.心房颤动患者可溶性血管紧张素转换酶2的新数据揭示了其在治疗新冠病毒肺炎和心血管疾病患者中的潜在价值。
Eur Heart J. 2020 Nov 1;41(41):4047-4049. doi: 10.1093/eurheartj/ehaa761.
4
Choosing Wisely: Cardiovascular Drug Therapy in the Era of COVID-19.
J Cardiovasc Pharmacol. 2020 Aug;76(2):123-124. doi: 10.1097/FJC.0000000000000875.
5
Effects of COVID-19 lockdown strategies on management of atrial fibrillation.2019冠状病毒病封锁策略对心房颤动管理的影响。
Eur Heart J. 2020 Sep 1;41(32):3080-3082. doi: 10.1093/eurheartj/ehaa538.
6
Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection.一名新型冠状病毒肺炎（COVID-19）感染患者的房性心律失常
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620925571. doi: 10.1177/2324709620925571.
7
TeleCheck-AF for COVID-19.用于新冠肺炎的TeleCheck-AF
Eur Heart J. 2020 Jun 1;41(21):1954-1955. doi: 10.1093/eurheartj/ehaa404.
8
Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis.心血管疾病作为新冠病毒感染风险增加及相关不良预后的生物标志物。
Biomark Med. 2020 Jun;14(9):713-716. doi: 10.2217/bmm-2020-0201. Epub 2020 May 19.
9
Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality.2019冠状病毒病（COVID-19）与心肌损伤及死亡率的关联
JAMA Cardiol. 2020 Jul 1;5(7):751-753. doi: 10.1001/jamacardio.2020.1105.
10
[COVID-19 disease. Cardiovascular risk or risk of bias?].[新冠肺炎。心血管风险还是偏倚风险？]
Medicina (B Aires). 2020;80(5):585-586.
引用本文的文献
1
Cardiac mechanics and the risk of atrial fibrillation in a community-based cohort of older adults.老年人群基于社区的队列中心脏力学与心房颤动风险。
Eur Heart J Cardiovasc Imaging. 2024 Nov 27;25(12):1686-1694. doi: 10.1093/ehjci/jeae162.
2
Left atrial strain importance in atrial fibrillation screening process.左心房应变在心房颤动筛查过程中的重要性。
Ann Cardiothorac Surg. 2024 Mar 29;13(2):173-175. doi: 10.21037/acs-2023-afm-0061. Epub 2023 Nov 16.
3
Long-Term Mortality after New-Onset Atrial Fibrillation in COVID-19.COVID-19患者新发房颤后的长期死亡率
J Clin Med. 2023 Apr 18;12(8):2925. doi: 10.3390/jcm12082925.
4
Prevalence and clinical implications of atrial fibrillation in patients hospitalized due to COVID-19: Data from a registry in Poland.因新型冠状病毒肺炎住院患者心房颤动的患病率及临床意义：来自波兰一项登记研究的数据
Front Cardiovasc Med. 2023 Mar 13;10:1133373. doi: 10.3389/fcvm.2023.1133373. eCollection 2023.
5
COVID-19 and comedications in atrial fibrillation-a case-control study in Stockholm.COVID-19 与心房颤动中的合并用药——斯德哥尔摩的病例对照研究。
Eur J Epidemiol. 2023 Mar;38(3):301-311. doi: 10.1007/s10654-023-00967-9. Epub 2023 Jan 28.
6
Atrial fibrillation is a risk factor for major adverse cardiovascular events in COVID-19.心房颤动是2019冠状病毒病（COVID-19）发生主要不良心血管事件的一个危险因素。
Int J Cardiol Heart Vasc. 2022 Sep 27;43:101127. doi: 10.1016/j.ijcha.2022.101127. eCollection 2022 Dec.
7
Cardiovascular manifestations secondary to COVID-19: A narrative review.COVID-19 相关心血管表现：综述。
Respir Med Res. 2022 May;81:100904. doi: 10.1016/j.resmer.2022.100904. Epub 2022 May 4.
8
Association between oral anticoagulants and COVID-19-related outcomes: a population-based cohort study.口服抗凝剂与 COVID-19 相关结局的关联：一项基于人群的队列研究。
Br J Gen Pract. 2022 Jun 30;72(720):e456-e463. doi: 10.3399/BJGP.2021.0689. Print 2022 Jul.
9
The prognostic role of interatrial block among COVID-19 patients hospitalized in medicine wards.医学病房中 COVID-19 住院患者的房间隔阻滞的预后作用。
Eur J Clin Invest. 2022 Aug;52(8):e13781. doi: 10.1111/eci.13781. Epub 2022 Apr 5.
10
Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19: A systematic review and meta-analysis.COVID-19 住院患者合并房性心律失常的结局和死亡率：系统评价和荟萃分析。
Cardiol J. 2022;29(1):33-43. doi: 10.5603/CJ.a2021.0167. Epub 2021 Dec 13.
本文引用的文献
1
Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients?心房颤动是否应被视为COVID-19患者预后较差的心血管危险因素？
Eur Heart J. 2020 Jul 1;41(32):3092-3093. doi: 10.1093/eurheartj/ehaa509.
2
COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.COVID-19 和心力衰竭：从感染到炎症和血管紧张素 II 刺激。从一种新疾病中寻找证据。
Eur J Heart Fail. 2020 Jun;22(6):957-966. doi: 10.1002/ejhf.1871. Epub 2020 Jun 24.
3
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy.意大利北部因 COVID-19 和心脏病住院患者的特征和结局。
Eur Heart J. 2020 May 14;41(19):1821-1829. doi: 10.1093/eurheartj/ehaa388.
4
Atrial Failure as a Clinical Entity: JACC Review Topic of the Week.心房衰竭作为一种临床实体：JACC 每周综述专题。
J Am Coll Cardiol. 2020 Jan 21;75(2):222-232. doi: 10.1016/j.jacc.2019.11.013.
5
Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling.血管紧张素转换酶 2 活性与人类心房颤动：血浆血管紧张素转换酶 2 活性增加与心房颤动和更严重的左心房结构重构相关。
Europace. 2017 Aug 1;19(8):1280-1287. doi: 10.1093/europace/euw246.
Zotero 插件